Liprostin

Phase 2Small molecule

EEndovasc

Liprostin is one of 9 small molecule programs targeting Arterial Occlusive Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Arterial Occlusive DiseaseActive, not recruiting

Arterial Occlusive DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Arterial Occlusive Disease

#DrugCompanyPhaseTrials

Plavix

Sanofi

Approved

—2

Caverject

VViatris Specialty LLC

Approved

1 3

Viagra

VViatris Specialty LLC

Reopro

Actovegin

1 6

Atacand

AstraZeneca

Preclinical

—7

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 8

Oxycontin

PProtega

Preclinical

1 9

Liprostin

EEndovasc

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Arterial Occlusive Disease1 trial

Prostaglandin E1 (Liprostin) Treatment With Lower Limb Angioplasty for Peripheral Arterial Occlusive Disease

Unknown status·EEndovasc·Phase 2·NCT00053716·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Liprostin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Liprostin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Liprostin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Endovasc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEndovasc

Liprostin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Arterial Occlusive Disease1 trial

References

Drug Info

Quick Facts

Related News